Which has stronger earnings & valuation, IBRX or ONC?

BeOne Medicines has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $113.29M 87.27 -$351.40M -$0.85 N/A BeOne Medicines $5.34B 6.11 $286.93M $4.47 66.59

Does the media refer more to IBRX or ONC?

In the previous week, ImmunityBio had 7 more articles in the media than BeOne Medicines. MarketBeat recorded 10 mentions for ImmunityBio and 3 mentions for BeOne Medicines. ImmunityBio's average media sentiment score of 0.37 beat BeOne Medicines' score of 0.35 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BeOne Medicines 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, IBRX or MRNA?

ImmunityBio has higher earnings, but lower revenue than Moderna. ImmunityBio is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $113.29M 87.27 -$351.40M -$0.85 N/A Moderna $1.94B 16.28 -$2.82B -$8.15 N/A

Is IBRX or MRNA more profitable?

Moderna has a net margin of -143.55% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets ImmunityBio -606.15% N/A -59.53% Moderna -143.55% -26.64% -19.32%

Does the media prefer IBRX or MRNA?

In the previous week, Moderna had 6 more articles in the media than ImmunityBio. MarketBeat recorded 16 mentions for Moderna and 10 mentions for ImmunityBio. Moderna's average media sentiment score of 0.55 beat ImmunityBio's score of 0.37 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 4 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IBRX or ROIV?

In the previous week, Roivant Sciences had 7 more articles in the media than ImmunityBio. MarketBeat recorded 17 mentions for Roivant Sciences and 10 mentions for ImmunityBio. Roivant Sciences' average media sentiment score of 0.56 beat ImmunityBio's score of 0.37 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 8 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IBRX or BNTX more profitable?

BioNTech has a net margin of -44.39% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat BioNTech's return on equity. Company Net Margins Return on Equity Return on Assets ImmunityBio -606.15% N/A -59.53% BioNTech -44.39% -5.30% -4.62%

Does the media prefer IBRX or BNTX?

In the previous week, ImmunityBio had 7 more articles in the media than BioNTech. MarketBeat recorded 10 mentions for ImmunityBio and 3 mentions for BioNTech. BioNTech's average media sentiment score of 0.89 beat ImmunityBio's score of 0.37 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioNTech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, IBRX or INSM?

ImmunityBio has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $113.29M 87.27 -$351.40M -$0.85 N/A Insmed $606.42M 39.89 -$1.28B -$5.75 N/A

Is IBRX or INSM more profitable?

Insmed has a net margin of -144.44% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets ImmunityBio -606.15% N/A -59.53% Insmed -144.44% -130.11% -51.57%

Does the media prefer IBRX or INSM?

In the previous week, ImmunityBio had 3 more articles in the media than Insmed. MarketBeat recorded 10 mentions for ImmunityBio and 7 mentions for Insmed. Insmed's average media sentiment score of 1.36 beat ImmunityBio's score of 0.37 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Insmed 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ImmunityBio (IBRX) Competitors

$9.44 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$9.40 -0.04 (-0.37%)

As of 07/2/2026 07:59 PM Eastern

Compare

IBRX vs. ONC, MRNA, ROIV, BNTX, and INSM

Should you buy ImmunityBio stock or one of its competitors? MarketBeat compares ImmunityBio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ImmunityBio include BeOne Medicines (ONC), Moderna (MRNA), Roivant Sciences (ROIV), BioNTech (BNTX), and Insmed (INSM). These companies are all part of the "pharmaceutical products" industry.

How does ImmunityBio compare to BeOne Medicines?

ImmunityBio (NASDAQ:IBRX) and BeOne Medicines (NASDAQ:ONC) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

ImmunityBio presently has a consensus target price of $14.20, indicating a potential upside of 50.42%. BeOne Medicines has a consensus target price of $390.00, indicating a potential upside of 31.03%. Given ImmunityBio's higher possible upside, equities research analysts plainly believe ImmunityBio is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

BeOne Medicines has a net margin of 8.94% compared to ImmunityBio's net margin of -606.15%. BeOne Medicines' return on equity of 12.06% beat ImmunityBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
BeOne Medicines	8.94%	12.06%	6.69%

In the previous week, ImmunityBio had 7 more articles in the media than BeOne Medicines. MarketBeat recorded 10 mentions for ImmunityBio and 3 mentions for BeOne Medicines. ImmunityBio's average media sentiment score of 0.37 beat BeOne Medicines' score of 0.35 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BeOne Medicines	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeOne Medicines has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	87.27	-$351.40M	-$0.85	N/A
BeOne Medicines	$5.34B	6.11	$286.93M	$4.47	66.59

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ImmunityBio has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market.

Summary

BeOne Medicines beats ImmunityBio on 12 of the 17 factors compared between the two stocks.

How does ImmunityBio compare to Moderna?

ImmunityBio (NASDAQ:IBRX) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

ImmunityBio has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market. Comparatively, Moderna has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

ImmunityBio has higher earnings, but lower revenue than Moderna. ImmunityBio is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	87.27	-$351.40M	-$0.85	N/A
Moderna	$1.94B	16.28	-$2.82B	-$8.15	N/A

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Moderna has a net margin of -143.55% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
Moderna	-143.55%	-26.64%	-19.32%

In the previous week, Moderna had 6 more articles in the media than ImmunityBio. MarketBeat recorded 16 mentions for Moderna and 10 mentions for ImmunityBio. Moderna's average media sentiment score of 0.55 beat ImmunityBio's score of 0.37 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	4 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

ImmunityBio currently has a consensus price target of $14.20, suggesting a potential upside of 50.42%. Moderna has a consensus price target of $37.13, suggesting a potential downside of 53.44%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts clearly believe ImmunityBio is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

Summary

ImmunityBio and Moderna tied by winning 8 of the 16 factors compared between the two stocks.

How does ImmunityBio compare to Roivant Sciences?

ImmunityBio (NASDAQ:IBRX) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

ImmunityBio has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

ImmunityBio has a net margin of -606.15% compared to Roivant Sciences' net margin of -3,629.19%. ImmunityBio's return on equity of 0.00% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

In the previous week, Roivant Sciences had 7 more articles in the media than ImmunityBio. MarketBeat recorded 17 mentions for Roivant Sciences and 10 mentions for ImmunityBio. Roivant Sciences' average media sentiment score of 0.56 beat ImmunityBio's score of 0.37 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	8 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by company insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Roivant Sciences has lower revenue, but higher earnings than ImmunityBio. Roivant Sciences is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	87.27	-$351.40M	-$0.85	N/A
Roivant Sciences	$8.26M	3,059.07	-$299.77M	-$0.60	N/A

ImmunityBio presently has a consensus target price of $14.20, suggesting a potential upside of 50.42%. Roivant Sciences has a consensus target price of $33.59, suggesting a potential downside of 4.38%. Given ImmunityBio's higher possible upside, equities analysts plainly believe ImmunityBio is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Roivant Sciences beats ImmunityBio on 10 of the 16 factors compared between the two stocks.

How does ImmunityBio compare to BioNTech?

ImmunityBio (NASDAQ:IBRX) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

ImmunityBio currently has a consensus target price of $14.20, suggesting a potential upside of 50.42%. BioNTech has a consensus target price of $129.56, suggesting a potential upside of 32.83%. Given ImmunityBio's higher possible upside, equities research analysts clearly believe ImmunityBio is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

BioNTech has a net margin of -44.39% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
BioNTech	-44.39%	-5.30%	-4.62%

In the previous week, ImmunityBio had 7 more articles in the media than BioNTech. MarketBeat recorded 10 mentions for ImmunityBio and 3 mentions for BioNTech. BioNTech's average media sentiment score of 0.89 beat ImmunityBio's score of 0.37 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

ImmunityBio has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	87.27	-$351.40M	-$0.85	N/A
BioNTech	$3.25B	7.60	-$1.29B	-$5.88	N/A

ImmunityBio has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market.

Summary

BioNTech beats ImmunityBio on 9 of the 17 factors compared between the two stocks.

How does ImmunityBio compare to Insmed?

ImmunityBio (NASDAQ:IBRX) and Insmed (NASDAQ:INSM) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

ImmunityBio has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	87.27	-$351.40M	-$0.85	N/A
Insmed	$606.42M	39.89	-$1.28B	-$5.75	N/A

ImmunityBio presently has a consensus price target of $14.20, suggesting a potential upside of 50.42%. Insmed has a consensus price target of $211.86, suggesting a potential upside of 89.84%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

Insmed has a net margin of -144.44% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
Insmed	-144.44%	-130.11%	-51.57%

In the previous week, ImmunityBio had 3 more articles in the media than Insmed. MarketBeat recorded 10 mentions for ImmunityBio and 7 mentions for Insmed. Insmed's average media sentiment score of 1.36 beat ImmunityBio's score of 0.37 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insmed	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

8.6% of ImmunityBio shares are held by institutional investors. 66.1% of ImmunityBio shares are held by company insiders. Comparatively, 2.1% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

ImmunityBio has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market. Comparatively, Insmed has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

Summary

Insmed beats ImmunityBio on 9 of the 17 factors compared between the two stocks.

Get ImmunityBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IBRX vs. The Competition

Export

Metric	ImmunityBio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.89B	$3.78B	$7.18B	$12.47B
Dividend Yield	N/A	2.16%	2.66%	6.50%
P/E Ratio	-11.11	21.61	28.02	24.70
Price / Sales	87.27	325.90	532.59	97.92
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	-18.51	8.66	10.96	6.46
Net Income	-$351.40M	$23.81M	$3.57B	$337.01M
7 Day Performance	8.38%	3.39%	2.12%	1.69%
1 Month Performance	36.42%	10.81%	5.25%	3.81%
1 Year Performance	249.63%	62.61%	33.29%	23.90%

ImmunityBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IBRX ImmunityBio	2.8015 of 5 stars	$9.44 flat	$14.20 +50.4%	+249.6%	$9.89B	$113.29M	N/A	590	News Coverage Insider Trade Gap Down
ONC BeOne Medicines	4.6703 of 5 stars	$291.67 +2.3%	$390.00 +33.7%	+21.2%	$32.00B	$5.34B	65.25	12,000	Analyst Forecast
MRNA Moderna	1.168 of 5 stars	$73.56 +5.0%	$37.13 -49.5%	+161.8%	$29.20B	$1.94B	N/A	4,700	Trending News Gap Down
ROIV Roivant Sciences	1.8287 of 5 stars	$35.06 -0.9%	$33.59 -4.2%	+223.9%	$25.20B	$8.26M	N/A	860	Insider Trade
BNTX BioNTech	3.8178 of 5 stars	$92.93 -0.1%	$129.56 +39.4%	-11.0%	$23.50B	$3.25B	N/A	7,807	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IBRX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ImmunityBio (IBRX) Competitors

IBRX vs. ONC, MRNA, ROIV, BNTX, and INSM

How does ImmunityBio compare to BeOne Medicines?

Summary

How does ImmunityBio compare to Moderna?

Summary

How does ImmunityBio compare to Roivant Sciences?

Summary

How does ImmunityBio compare to BioNTech?

Summary

How does ImmunityBio compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBRX vs. The Competition

ImmunityBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ImmunityBio (IBRX) Competitors

IBRX vs. ONC, MRNA, ROIV, BNTX, and INSM

How does ImmunityBio compare to BeOne Medicines?

Do analysts rate IBRX or ONC?

Is IBRX or ONC more profitable?

Does the media refer more to IBRX or ONC?

Which has stronger earnings & valuation, IBRX or ONC?

Do insiders & institutionals believe in IBRX or ONC?

Which has more volatility and risk, IBRX or ONC?

Summary

How does ImmunityBio compare to Moderna?

Which has more risk & volatility, IBRX or MRNA?

Which has stronger earnings and valuation, IBRX or MRNA?

Do institutionals and insiders hold more shares of IBRX or MRNA?

Is IBRX or MRNA more profitable?

Does the media prefer IBRX or MRNA?

Do analysts rate IBRX or MRNA?

Summary

How does ImmunityBio compare to Roivant Sciences?

Which has more volatility & risk, IBRX or ROIV?

Is IBRX or ROIV more profitable?

Does the media prefer IBRX or ROIV?

Do institutionals & insiders hold more shares of IBRX or ROIV?

Which has better valuation and earnings, IBRX or ROIV?

Do analysts recommend IBRX or ROIV?

Summary

How does ImmunityBio compare to BioNTech?

Do analysts recommend IBRX or BNTX?

Do insiders & institutionals hold more shares of IBRX or BNTX?

Is IBRX or BNTX more profitable?

Does the media prefer IBRX or BNTX?

Which has higher earnings & valuation, IBRX or BNTX?

Which has more risk and volatility, IBRX or BNTX?

Summary

How does ImmunityBio compare to Insmed?

Which has higher valuation and earnings, IBRX or INSM?

Do analysts rate IBRX or INSM?

Is IBRX or INSM more profitable?

Does the media prefer IBRX or INSM?

Do insiders and institutionals hold more shares of IBRX or INSM?

Which has more risk and volatility, IBRX or INSM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBRX vs. The Competition

ImmunityBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools